A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease (EASi-PROTKT™)

drug protocol number

1378-0041

drug sponsor

Boehringer Ingelheim / IQIVIA

drug study

Vicadrostat (BI 690517) / Empagliflozin

drug trial site

Imam Abdulrahman University Hospital (Dammam) , King Abdulaziz University Hospital (Jeddah) , King Faisal Specialist Hospital and Research Center (Riyadh) , King Saud University Medical City (Riyadh)

drug status

Ongoing

drug phase